Palisade Bio (PALI) Share-based Compensation (2010 - 2026)
Palisade Bio's (PALI) quarterly Share-based Compensation came in at $4.3 million in Q1 2026, up 7438.6% year-on-year from $57000.0 in Q1 2025, and up 15.45% on a QoQ basis from $3.7 million in Q4 2025.
Palisade Bio (PALI) Share-based Compensation (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has 17 years of Share-based Compensation data on file, last reported at $4.3 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 7438.6% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $7.6 million, a 4813.58% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 1862.0% from the prior year.
- Share-based Compensation for Q1 2026 stood at $4.3 million, up from $3.7 million in the prior quarter.
- Over the last five years, Share-based Compensation for PALI reached as high as $4.3 million in Q1 2026 and fell as low as -$440000.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $589470.6 across 5 years, with a median of $185000.0 in 2023.
- Across the five-year window, Share-based Compensation tumbled 337.84% in 2024 and jumped 7438.6% in 2026, its largest moves.
- Year by year, Share-based Compensation stood at $86000.0 in 2022, then soared by 115.12% to $185000.0 in 2023, then tumbled by 337.84% to -$440000.0 in 2024, then soared by 945.91% to $3.7 million in 2025, then increased by 15.45% to $4.3 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $4.3 million in Q1 2026, $3.7 million in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Palisade Bio | 985.76 | -132.63 Mn | - | 4.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.30 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Dec 31, 2025 | 3.72 Mn |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Dec 31, 2024 | -440,000.00 |
| Dec 31, 2024 | -440,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Jun 30, 2024 | 129,000.00 |
| Mar 31, 2024 | 118,000.00 |
| Mar 31, 2024 | 118,000.00 |
| Dec 31, 2023 | 185,000.00 |
| Dec 31, 2023 | 185,000.00 |